Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KALV NASDAQ:PTCT NASDAQ:TGTX NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKALVKalVista Pharmaceuticals$26.73+0.0%$19.11$9.83▼$26.84$1.37B-0.122.20 million shs810,050 shsPTCTPTC Therapeutics$75.29+16.7%$67.69$43.17▼$87.50$6.24B0.531.20 million shs1.56 million shsTGTXTG Therapeutics$44.02+2.3%$32.72$25.28▼$44.62$6.78B1.682.09 million shs610,466 shsXENEXenon Pharmaceuticals$56.56+1.0%$54.64$28.19▼$63.95$5.47B0.651.26 million shs218,138 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKALVKalVista Pharmaceuticals0.00%+0.23%+32.80%+79.33%+118.12%PTCTPTC Therapeutics-3.11%-0.88%-7.32%-13.64%+58.32%TGTXTG Therapeutics+2.53%+27.38%+28.87%+49.10%+23.47%XENEXenon Pharmaceuticals-4.53%-0.07%-2.86%+35.33%+58.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKALVKalVista Pharmaceuticals$26.73+0.0%$19.11$9.83▼$26.84$1.37B-0.122.20 million shs810,050 shsPTCTPTC Therapeutics$75.29+16.7%$67.69$43.17▼$87.50$6.24B0.531.20 million shs1.56 million shsTGTXTG Therapeutics$44.02+2.3%$32.72$25.28▼$44.62$6.78B1.682.09 million shs610,466 shsXENEXenon Pharmaceuticals$56.56+1.0%$54.64$28.19▼$63.95$5.47B0.651.26 million shs218,138 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKALVKalVista Pharmaceuticals0.00%+0.23%+32.80%+79.33%+118.12%PTCTPTC Therapeutics-3.11%-0.88%-7.32%-13.64%+58.32%TGTXTG Therapeutics+2.53%+27.38%+28.87%+49.10%+23.47%XENEXenon Pharmaceuticals-4.53%-0.07%-2.86%+35.33%+58.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKALVKalVista Pharmaceuticals 2.22Hold$30.6014.50% UpsidePTCTPTC Therapeutics 2.64Moderate Buy$88.2117.17% UpsideTGTXTG Therapeutics 2.57Moderate Buy$52.5019.26% UpsideXENEXenon Pharmaceuticals 3.00Buy$73.0029.07% UpsideCurrent Analyst Ratings BreakdownLatest KALV, XENE, TGTX, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026PTCTPTC Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/8/2026PTCTPTC Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$90.005/8/2026PTCTPTC Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$86.00 ➝ $95.005/8/2026XENEXenon Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$80.00 ➝ $78.005/6/2026TGTXTG Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $70.005/1/2026TGTXTG Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/1/2026KALVKalVista Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$37.00 ➝ $27.005/1/2026TGTXTG Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/30/2026KALVKalVista Pharmaceuticals JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/30/2026KALVKalVista Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/29/2026KALVKalVista Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKALVKalVista Pharmaceuticals$1.43M959.96N/AN/A$2.71 per share9.86PTCTPTC Therapeutics$1.73B3.61$9.92 per share7.59($2.56) per share-29.41TGTXTG Therapeutics$700.35M9.62$2.94 per share14.98$4.08 per share10.79XENEXenon Pharmaceuticals$7.50M728.80N/AN/A$7.53 per share7.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKALVKalVista Pharmaceuticals-$109.52M-$3.95N/A45.30N/AN/A-214.88%-81.87%5/11/2026 (Estimated)PTCTPTC Therapeutics$682.64M$7.749.7360.72N/A39.44%-362.45%25.21%N/ATGTXTG Therapeutics$447.18M$2.8615.4717.97N/A65.95%91.89%50.43%N/AXENEXenon Pharmaceuticals-$345.91M-$4.36N/AN/AN/AN/A-55.81%-52.04%N/ALatest KALV, XENE, TGTX, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026N/AKALVKalVista Pharmaceuticals-$0.3763-$0.92-$0.5438N/A$39.14 million$13.69 million5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$218.80 million$272.55 million5/7/2026Q1 2026XENEXenon Pharmaceuticals-$1.17-$1.17N/A-$1.17$1.36 millionN/A5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.12-$0.11$0.12$200.33 million$204.92 million2/26/2026Q4 2025TGTXTG Therapeutics$0.35$0.14-$0.21$0.14$192.15 million$192.57 million2/26/2026Q4 2025XENEXenon Pharmaceuticals-$1.20-$1.31-$0.11-$1.31N/AN/A2/19/2026Q4 2025PTCTPTC Therapeutics-$0.21-$1.67-$1.46-$1.67$281.45 million$164.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKALVKalVista Pharmaceuticals8.187.227.21PTCTPTC TherapeuticsN/A2.352.27TGTXTG Therapeutics0.384.103.29XENEXenon PharmaceuticalsN/A13.4113.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKALVKalVista PharmaceuticalsN/APTCTPTC TherapeuticsN/ATGTXTG Therapeutics58.58%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipKALVKalVista Pharmaceuticals4.30%PTCTPTC Therapeutics5.50%TGTXTG Therapeutics10.64%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKALVKalVista Pharmaceuticals10051.22 million49.02 millionOptionablePTCTPTC Therapeutics1,41082.91 million78.35 millionOptionableTGTXTG Therapeutics290153.09 million136.81 millionOptionableXENEXenon Pharmaceuticals21096.64 million92.71 millionOptionableKALV, XENE, TGTX, and PTCT HeadlinesRecent News About These CompaniesNeedham & Company LLC Cuts Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $78.002 hours ago | marketbeat.comXenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call TranscriptMay 8 at 4:01 AM | seekingalpha.comXenon Pharmaceuticals: Q1 Earnings SnapshotMay 7 at 10:59 PM | finance.yahoo.comXenon (XENE) Q1 2026 Earnings TranscriptMay 7 at 10:59 PM | finance.yahoo.comXenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings ResultsMay 7 at 10:49 PM | marketbeat.comXenon Reports Q1 2026 Financial Results and Provides Business UpdateMay 7 at 4:01 PM | globenewswire.comXenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026May 7 at 8:44 AM | globenewswire.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from BrokeragesMay 6 at 3:15 AM | marketbeat.comXenon Pharmaceuticals (XENE) Projected to Post Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comJennison Associates LLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENEMay 1, 2026 | marketbeat.comPictet Asset Management Holding SA Cuts Position in Xenon Pharmaceuticals Inc. $XENEMay 1, 2026 | marketbeat.comXenon to Report Q1 2026 Financial Results on May 7, 2026April 30, 2026 | globenewswire.comXenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)April 30, 2026 | marketbeat.comXenon Pharmaceuticals Highlights Strong Phase III Azetukalner Data, Q3 NDA Plans at Bloom Burton ConferenceApril 26, 2026 | marketbeat.comPeregrine Capital Management LLC Invests $7.84 Million in Xenon Pharmaceuticals Inc. $XENEApril 24, 2026 | marketbeat.comXenon Pharmaceuticals Inc (XENE) Looking At a $2 Billion Opportunity HereApril 23, 2026 | insidermonkey.comXenon's Phase 3 Supports A 'Buy' Despite Its PremiumApril 22, 2026 | seekingalpha.comXenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal ...April 19, 2026 | caledonianrecord.comCXenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results for Azetukalner in Focal Onset Seizures at AAN 2026April 19, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKALV, XENE, TGTX, and PTCT Company DescriptionsKalVista Pharmaceuticals NASDAQ:KALV$26.72 +0.01 (+0.02%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.PTC Therapeutics NASDAQ:PTCT$75.29 +10.80 (+16.75%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.TG Therapeutics NASDAQ:TGTX$44.02 +0.99 (+2.31%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.Xenon Pharmaceuticals NASDAQ:XENE$56.56 +0.56 (+1.00%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
